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Copy number aberrations frequently occur during the development of many cancers. Such
events affect dosage of involved genes and may cause further genomic instability and pro-
gression of cancer. In this survey, canine SNP microarrays were used to study 117 canine
mammary tumours from 69 dogs.
Results
We found a high occurrence of copy number aberrations in canine mammary tumours,
losses being more frequent than gains. Increased frequency of aberrations and loss of het-
erozygosity were positively correlated with increased malignancy in terms of histopatholog-
ical diagnosis. One of the most highly recurrently amplified regions harbored theMYC gene.
PTEN was located to a frequently lost region and also homozygously deleted in five tu-
mours. Thus, deregulation of these genes due to copy number aberrations appears to be an
important event in canine mammary tumour development. Other potential contributors to
canine mammary tumour pathogenesis are COL9A3, INPP5A, CYP2E1 and RB1. The pres-
ent study also shows that a more detailed analysis of chromosomal aberrations associated
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with histopathological parameters may aid in identifying specific genes associated with ca-
nine mammary tumour progression.
Conclusions
The high frequency of copy number aberrations is a prominent feature of canine mammary
tumours as seen in other canine and human cancers. Our findings share several features
with corresponding studies in human breast tumours and strengthen the dog as a suitable
model organism for this disease.
Background
Cancer is the most frequent cause of disease-associated death in dogs, and naturally occurring
cancer is well described in several breeds [1,2]. Canine mammary tumours (CMTs), which are
among the most common canine cancer forms [3], are often seen in elderly, intact bitches
[4,5]. A higher incidence in certain breeds such as the English Springer Spaniel, Boxer, Cocker
Spaniel and Dachshund [4–9] strongly suggests an underlying genetic predisposition. Howev-
er, CMT-associated genetic risk factors largely remain to be identified. Comparing canine and
human mammary cancers, the latter are dominated by epithelial tumours, while CMTs fre-
quently also contain myoepithelial and mesenchymal components [10]. Further, regional
lymph node metastasis has been reported to be a less important prognostic factor in dogs than
in humans [11]. Nevertheless, canine and human mammary cancers share important clinical
and pathophysiologic characteristics: a spontaneous occurrence of tumours that primarily af-
fect females, hormonal influence on tumour development (e.g. oestrogen and progesterone),
histopathological similarities, broadly equal metastatic spread, and potentially also mutual
prognostic markers and genetic risk factors for disease [10,11].
Since their domestication from the wolf, dogs have continuously undergone artificial selec-
tion [12–14]. Most breeds are descended from a small number of founders and popular sires
[15]. As a result, genetic isolated populations of breeds have developed, many at increased risk
of specific genetic disorders [13,16–19]. The breed structure of the dog with low genetic hetero-
geneity within breeds and long linkage disequilibrium (LD), combined with the enrichment of
specific disease-associated alleles within certain breeds, is an advantage in mapping/identifica-
tion of genes of interest for genetic disorders.
Cancer genomes are typically characterized by numerous sequence changes compared with
their normal host counterparts. An important example of such changes is the accumulation of
copy number alterations, a key event in the development and progression of many cancers.
Such alterations range from single nucleotide insertions or deletions to gain or loss of large
chromosomal fragments, and even whole-genome duplications [20,21]. Detection of recurrent
DNA copy number alterations (CNAs) and identification of the genes affected by such alter-
ations can reveal underlying mechanisms of disease evolution and might be of diagnostic, prog-
nostic and therapeutic significance. Human breast cancer is a heterogeneous disease with
established subtypes based on gene expression profiling [22,23]. Distinct spectra of CNAs have
been shown to underlie each of these subtypes. This strongly suggests that tumours of different
subtypes develop along specific genetic pathways [24–28] and that different mechanisms of ge-
nomic instability give rise to the different breast tumours subtypes and may contribute to their
characteristic biological and clinical behavior [26]. Genetic subtypes of CMTs based on expres-
sion analysis and CNAs remain to be defined, although immunohistochemical analysis
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indicates that some of the same subgroups can be found in canine mammary neoplasms
[29,30]. Further, previous studies have demonstrated that CNAs in a variety of human cancers
are recurrently observed in the corresponding canine cancer [31–33]. A recent study of genome
aberrations in canine mammary carcinomas also reported similarities to human breast cancer
as well as specific canine alterations [34]. Defining aberrant genomic regions in canine tumours
and subsequent comparative molecular analysis in human provides an opportunity to gain
deeper insight into pathways implicated in mammary tumourigenesis in both species and to re-
veal additional regions not yet identified in human breast cancer. It may also be an important
step in the work towards developing new cancer treatments.
In the present survey, we aimed to identify regions and genes associated with canine mam-
mary tumour initiation and progression. To our knowledge, this is the first study of allele-
specific copy number in canine mammary tumours. Significance analysis of the aberrant re-
gions was also performed.
Materials and Methods
Ethics Statement
The blood and tumour samples of the present study were collected by certified veterinarians at
private veterinary clinics in Norway during routine clinical and mammary tumour surgery pro-
cedures, and in agreement with the provisions enforced by the Norwegian Animal Research
Authority and the Norwegian Regulation on Animal Experimentation [35].
Samples
DNA from blood and mammary tumour samples from 69 dogs of different breeds were includ-
ed in the study. These were privately owned dogs presented to a veterinarian due to the occur-
rence of mammary tumours. From 46 of the dogs we had DNA from multiple tumours (44
with two and two with three tumours) and 23 dogs were represented by one tumour, in total
117 tumours. Two biopsies of maximum 0.5cm3 were taken next to each other from the tu-
mours that had been surgically removed from the dogs. One biopsy was submerged in formalin
and the other in RNAlater (Ambion, Applied Biosystems, Austin, Texas, USA). All the biopsies
were mailed to the Norwegian School of Veterinary Science (NSVS), and the RNAlater biopsies
were frozen at -80 degrees at arrival. The formalin biopsies were paraffin-embedded, sectioned
by microtome and stained (hematoxylin-eosin and van Gieson). All the tumour sections were
examined and classified by one pathologist (GG) according to the latest proposal for WHO
guidelines for CMTs [36] (Gjermund Gunnes, Kaja S. Borge, Frode Lingaas; submitted). Each
tumour sample was examined for tumour size, growth pattern, secondary changes, cell and tis-
sue types, nucleus, and invasive growth into tumour stroma. Tumor size was scored from 1 to
3, where 1: tumours<1 cm in diameter 2: tumours between 1 and 2.9 cm in diameter, and 3:
tumours>3 cm in diameter. Growth pattern included hyperplasia and solid growth of the epi-
thelial component. It was evaluated from 1 to 3, where 0: not observed, 1:< 25% of section
area, 2: 25–90% of section area, and 3:> 90% of section area. Secondary changes like connec-
tive tissue, inflammation and necrosis was evaluated from 0 to 3, where 0: not observed, 1:<
10% of section area, 2: 10–75% of section area, and 3:> 75% of section area. The nucleus
groups included nuclear pleomorphism, mitotic index and mitotic morphology. All three pa-
rameters were scored from 0 to 3. For nuclear pleomorphism, 0: no irregular nuclei, 1: small de-
gree of variation in nuclear shape and size, and occasional nucleoli, 2: moderate degree of
variation in nuclear shape and size, and presence of nucleoli, and 3: high degree of variation in
nuclear shape and size, and numerous prominent nucleoli. For mitotic index, 0: no observed
mitotic figures in 10 HPF, 1: fewer than 10 mitotic figures per 10 HPF, 2: 10 to 19 mitotic
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figures per 10 HPF, and 3: 20 or more mitotic figures per 10 HPFF. For mitotic morphology
(number of mitoses with abnormal mitotic morphology), 0: none, 1: few, 2: moderate amounts,
3: numerous. The parameters in the cell and tissue type group (epithelial cells, myoepithelial
cells, chondroid tissue, osteoid tissue) and invasive growth into tumour stroma were scored on
a binomial scale where 0: not observed and 1: observed. The most common benign and
malignant diagnosis in the present material of 117 tumours were complex adenoma (adeno-
myoepithelioma) (n = 26) and complex carcinoma (n = 17), respectively. A method for simul-
taneous extraction of RNA and DNA from small biopsies was applied to the RNAlater-tumour
biopsies. RNA was first isolated according to the protocol described by Riis et al. [37]. Thereaf-
ter, DNA was extracted from the interphase/organic phase left after RNA isolation through the
following steps: Back extraction buffer [38] was used to separate the phases, isopropanol added
to precipitate DNA, and the precipitated DNA transferred to DNeasy Mini columns (Qiagen,
Hilden, Germany). Further processing was performed according to Qiagen’s protocol, and the
purified DNA was eluted with water. DNA quantity and quality was measured by NanoDrop
(Thermo Fisher Scientific, Wilmington, Pennsylvania, USA) and diluted to a concentration of
50ng/μl. The DNA was used for the array analysis of the present study, while the RNA was
saved at -80 degrees for use in future analysis.
Array analysis
Illumina CanineHD Genotyping BeadChips, 170K (Illumina, Inc., San Diego, CA, USA), were
used for analysis of the blood and tumour samples. The hybridized arrays were scanned by Illu-
mina BeadArray Reader and the scanning results imported into GenomeStudio Genotyping
Module. All samples were custom clustered in GenomeStudio using the blood samples as refer-
ence. Estimated B allele frequencies (BAF) and Log R Ratios (LRR) for both blood and tumour
samples were used for further analysis (original BAF and LRR values are publically available in
the Dryad repository: doi:10.5061/dryad.7dm4d [39,40]).
Copy number and significance analysis
Tumour LRR values frequently display some bias that can be related to local variations in the
GC content and which appears visually as a waving pattern when LRR is plotted against geno-
mic location [41]. As this bias can distort the statistical analysis, the GC correction method im-
plemented in PennCNV [41] was first applied to the data. Next, the arrays were quantile
normalized to a normal reference distribution to reduce the effect of technical artifacts that
manifest themselves as skewness in the LRR distribution of many arrays (GC corrected, quan-
tile normalized LRR values are available in the Dryad repository: doi:10.5061/dryad.7dm4d
[39,40]). The subsequent analysis considered all tumours in the material collectively, as well as
different subgroupings: (1) three subgroups defined as hyperplasias (n = 13, including two duct
ectasias and two fibroadenomatous changes), benign tumours (n = 57) and malignant tumours
(n = 47); (2) groups of morphologically similar diagnosis (Table 1); and (3) six histopatholog-
ical parameters of malignancy.
To evaluate genome-wide gains and losses, we first segmented the data using the Piecewise
Constant Fit (PCF) algorithm in the Bioconductor package Copynumber [42] with penalty pa-
rameter gamma = 80 and at least kmin = 10 probes per segment. Following the recommenda-
tions of the package, the segmentation was preceded by Winsorization (also available in
Copynumber) to handle extreme outliers. As the Copynumber package is adapted to human
data with 23 chromosomes, the canine data were split in two sets (canine chromosome (CFA)
1–19 and CFA20-38 + X) for winsorization and segmentation and were subsequently joined
before further frequency analysis of gains and losses. Aberrations were defined as segmented
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copy number values above 0.05 (gain) or below -0.05 (loss). Regions with aberrations occurring
in20% of the tumours were defined as recurrent and further analyzed and compared to the
UCSC reference gene list for CanFam 2.0 [43] to identify gained and lost genes. The gained/
lost gene lists were compared to the Cancer Gene Census working list of known cancer genes
in humans [44]. Similar analysis was performed for the three subgroups of hyperplasias, benign
and malignant tumours.
To further investigate the structure of the copy number alterations, we applied the Allele-
Specific Copy Number Analysis of Tumours (ASCAT) [24,45]. ASCAT was performed accord-
ing to Van Loo, Nordgard et al. [24] to estimate tumor purity and ploidy and dissect the allele-
specific copy number of the CMTs. Genome-wide ASCAT profiles were calculated for each tu-
mour. Germline BAF, germline LRR, tumour BAF and GC corrected, quantile normalized tu-
mour LRR was used as input data for the ASCAT analysis (ASPCF penalty parameter = 0.80,
ASCAT gamma = 0.40, ASCAT version 2.2). Based on the ASCAT output, frequency of gains,
losses and loss of heterozygosity (LOH) were calculated as described by Van Loo, Nordgard
et al. [24]. Regions with aberrations occurring in20 tumours were defined as recurrent and
further analyzed and compared to the UCSC reference gene list for CanFam 2.0 [43] to identify
gained and lost genes. UCSC Batch Coordinate Conversion (liftOver) [46] and Ensembl [47]
was used to analyze orthology to the human genome. Analysis of ploidy and aberrant cell frac-
tion were performed in R [48] for different malignancy subgroups (hyperplasias, benign and
malignant tumours) and groups of tumours of morphological similar diagnosis (Table 1). In
addition, the pattern of CNAs was studied at the chromosome level for the following histo-
patholgical parameters: solid growth of the epithelial component in the tumour (no/yes), pres-
ence of myoepithelial cells in the tumour (no/yes), invasive growth of neoplastic cells into
tumour stroma (no/yes), nuclear pleomorphism (no/moderate-severe), mitotic index (0/above
9 per 10 high-power fields (HPF)) and presence of necrosis in tumour (no/yes). Solid growth
(lack of tubular formation), invasive growth into tumour stroma, increased nuclear pleomor-
phism and mitotic index, presence of necrosis and absence of myoepithelial cell proliferation
are all associated with malignancy and/or poor prognosis in mammary tumours [49–51].
These parameters were part of a larger morphological classification system used to evaluate
and diagnose the CMTs of the present study (Gjemund Gunnes, Kaja S. Borge, Frode Lingaas;
submitted) (histopathomorphological scoring values for these six parameters for all tumours
Table 1. Groups of morphologically related diagnosis used for analysis.
Diagnosis group Tumour diagnoses included N
Non-neoplastic tumours Hyperplasias, ectasias and other non-neoplastic
diagnoses of the mammary tissue
12
Benign neoplasias Simple adenomas (incl. basaloid and intraductal
papillary adenomas), complex adenomas, benign mixed
tumours
55
Transitional tumours Carcinoma in situ, carcinoma arising in benign tumor 6
Malignant epithelial tumours with
myoepithelial and mesenchymal
components
Complex carcinomas and mixed carcinomas,
carcinosarcoma, carcinoma and malignant
myoepithelioma
18
Malignant purely epithelial with tubular
formations
Simple carcinomas (tubular, tubulopapillary, cystic-
papillary, cribriform) and ductal carcinoma
18
Malignant purely epithelial with loss of




N = Number of tumours.
doi:10.1371/journal.pone.0126371.t001
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with an ASCAT output are available in the DRYAD repository: doi:10.5061/dryad.7dm4d
[39,40]). The difference between the subgroups of each parameter (no/yes, no/moderate-se-
vere, 0/above 9 pr. 10 HPF) was calculated by subtracting the aberration frequency of the first
subgroup from that of the second. An exception was made for the myoepithelial cell presence,
where the CNA frequency of the second group (“yes”) was subtracted from the first (“no”).
Chromosome regions with such a difference in aberration frequency of20% were registered
and further studied.
To investigate the significant peak regions for amplification or deletion, i.e. regions that are
more likely to contain “driver mutations” for CMTs, the original idea of the numerical algo-
rithm called GISTIC (Genomic Identification for Significant Targets [52]) was applied to the
data. However, since GISTIC has been developed to identify broad/focal regions of the genome
that are significantly amplified or deleted across a set of human samples, it was difficult to
adapt to our canine data. Therefore, the basic numerical algorithm of GISTIC was applied to
the GC corrected, quantile normalized tumour LRR values in this study. The calculation proce-
dure is summarized as following: (1) Take the sum of the segmented data across all samples for
each genomic location, (2) Generate permutated data across genomic locations and apply the
same procedure 1 to the data for each genomic location, (3) Repeat 2 for 1000 times to generate
the null distribution, (4) Find the location satisfied |the value by 1|> the value by 3 for each
genomic location and calculate the p-values, and (5) Apply FDR [53] (e.g.5%) for the p-values
obtained by 4 and find the significant genomic location. For these analysis purposes, the syn-
chronous tumour pairs from the same dog were split into two different data sets since tumours
from the same dog possibly are biologically related and thus not statistically independent ob-
servations. The single tumours were included in both sets. The analysis was also performed for
a third data set of all tumours together (both single and all the paired tumours). The results
from the independent analyses of all three data sets were compared
Results
Recurrent gains and losses identified by segmentations
Several regions of gain and loss were identified by the PCF segmentation analysis. In the recur-
rently gained regions, 80 genes were identified (S1 Table), of which seven were found in the
Cancer Gene Census list [44] (Table 2). These seven were all genes with dominant effect, in-
cluding well-known oncogenes like FGFR2 andMYC. The recurrently lost regions contained
482 genes (S2 Table) of which six were tumour suppressor genes also found in the Cancer
Gene Census list (Table 2). The frequency of aberrations increased with malignancy; the num-
ber of recurrently gained/lost region was lowest in hyperplasias and highest in malignant tu-
mours (data not shown). Genes from the Cancer Gene Census list that were found in the
recurrently aberrant regions for hyperplasias, benign and malignant tumours are presented in
Table 3.
ASCAT
ASCAT profiles were obtained for 113 tumours, of which 12 were hyperplasias/ectasias, 55 be-
nign and 46 malignant neoplasias.
Ploidy. A mean ASCAT ploidy estimate of 2.4 was found across all tumours. Eighty-four
(~74%) of the tumours were diploid (ploidy close to 2; 1.8–2.2) and 29 (~26%) were aneuploid
(ploidy<1.8 or>2.2). Of the aneuploid tumours, two (~2%) were hypodiploid (ploidy<1.8),
ten (~9%) tetraploid (ploidy close to 4; 3.8–4.2) and two (~2%) highly polyploid (ploidy>4.2).
The proportion of the hyperplasias, benign and malignant tumours with aneuploidy was
~17%, 26% and 28%, respectively. Tumours of a benign CMT diagnosis most often had
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a ploidy estimate of either ~2 or ~4, while a substantial part of the malignant tumours had a
ploidy of ~3 (Fig 1).
Aberrant cell fraction. The estimated aberrant cell fraction (percentage of tumour cells)
from the ASCAT profiles ranged from 24% to 100%, with a mean of 62%. In general, malignant
tumours tended to have a higher proportion of aberrant cells (mean of 65%) than benign
(mean 61%) and hyperplasias (mean 53%) (Fig 2).
Regions with gains and losses. According to the ASCAT analysis, losses were more highly
recurrent than gains (recurrent region defined as aberration found in 20 tumours) (Fig 3).
The two regions with the most frequent DNA copy number gains were located on CFA9 and
13. These were 1.4Mb and 19.4Mb in size, respectively. The well-known oncogeneMYC was lo-
cated in the most highly recurrently gained region on CFA13. No annotated canine gene was
located in the very frequently gained region on CFA9 (19.863–20.922Mb). The region showed
Table 2. Genes with known cancer-association in humans found in recurrently gained/lost regions in CMTs.
Gene Human chromosome Canine chromosome Genetic effects Aberration in CMT analysis
BCL6 3 34 Dominant Gain
FGFR2 10 28 Dominant Gain
FHIT 3 20 Dominant Gain
MITF 3 20 Dominant Gain
MYC 8 13 Dominant Gain
NPM1 5 4 Dominant Gain
PDGFRB 5 4 Dominant Gain
BMPR1A 10 4 Recessive Loss
KDM5C X X Recessive Loss
KDM6A X X Recessive Loss
MEN1 11 18 Recessive Loss
PRF1 10 4 Recessive Loss
SDHB 1 2 Recessive Loss
Results from the PCF analysis. The Cancer Gene Census List was used as reference for genes with known cancer-association in humans [44].
doi:10.1371/journal.pone.0126371.t002




Gained genes Lost genes
Hyperplasias FHIT, MITF, MYC, NPM1 AKT2, BIRC3, BMPR1A, CCND1, GNA11,
KDM5C, KLK2, MEN1, MYH9, PDGFB,
PPARG, PRF1, SDHB, TFRC, ZNF331
Benign
tumours
FGFR2, FHIT, MITF, MYC, NPM1,
PDGFRB
AKT2, BMPR1A, CCND1, GNA11,
HMGA1, KDM5C, KDM6A, KLK2, MEN1,




BCL2, BCL6, CTNNB1, FGFR2, FHIT,
GNAQ, GNAS, KDR, KIT, LIFR, MET,
MITF, MYC, NPM1, PDGFRB
AKT2, BIRC3, BMPR1A, BRCA1, CCND1,
COL1A1, ERBB2, GNA11, HMGA1,
KDM5C, KDM6A, KLK2, MEN1, MUC1,
MYH9, PDGFB, PIM1, PRF1, PTEN, RARA,
SDHB, TFRC, ZNF331
Results from the PCF analysis. Genes with recessive molecular genetic function are underlined, otherwise
dominant genes [44].
doi:10.1371/journal.pone.0126371.t003
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orthology to human chromosome (HSA) 17q (68.433–69.684Mb, hg19), that contained no an-
notated protein-coding genes in humans. However, the human non-protein coding gene
CASC17 (“cancer susceptibility candidate 17”) was located to this region. The regions that
most often harboured deletions were located on CFA1, 7, 8, 9, 13, 14, 15, 17, 18, 20, 22, 24, 26,
28, 31, 33 and X. Nine of these were losses of chromosome ends/included telomeric regions
(CFA8, 18, 20, 24, 26, 28, 31, 33 and X). The proportion of tumours with loss of the CFA18
chromosome end increased with malignancy. Such a loss occurred in approximately 8%, 13%
and 30% of hyperplasias, benign and malignant tumours, respectively. For the rest of the chro-
mosomes with loss of ends, these were also frequently seen in hyperplasias and benign tu-
mours. One known cancer-associated gene, the tumour suppressor geneMEN1, was located in
the highly recurrently lost regions. Losses in chromosome regions of well-known tumour sup-
pressor genes like BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PTEN, RB1 and TP53 were found in
18 (16.9%), 3 (2.7%), 16 (14.2%), 12 (10.6%), 10 (8.8%), 17 (15.0%), 11 (9.7%) and 4 (3.5%)
tumours, respectively.
Similar to the PCF analysis, an increased frequency of aberrations was generally observed
for increased malignancy of diagnosis for the ASCAT results (Fig 4). Gain ofMYC was seen in
two (16.7%) hyperplasias, 5 (9.1%) benign tumours and 14 (30.4%) malignant tumours. The
number and frequency of aberrations also increased from lower grade malignant tumours to
the most high-grade malignant tumours (data not shown). The most malignant tumours, solid
and anaplastic carcinomas (n = 4), were found to have a higher frequency of whole-chromo-
some gains and losses compared to the others (data not shown).
Fig 1. ASCAT estimate of ploidy in different subgroups of tumours.Hyperplasias (n = 12), benign
(n = 55) and malignant tumours (n = 46). For the graphical presentation, the ploidy estimates were rounded to
the nearest whole number.
doi:10.1371/journal.pone.0126371.g001
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Significance analysis of aberrant regions
As described in the materials and methods, this analysis applying the method for GISTIC was
performed for three different sample selections: in the first two data sets, the tumour pairs were
split between selection one and two, while the single tumours were included in both selections.
Fig 2. ASCAT estimate of percentage of aberrant cells in different subtypes of tumours.Hyperplasias
(n = 12), benign tumours (n = 55) and malignant tumours (n = 46).
doi:10.1371/journal.pone.0126371.g002
Fig 3. Recurring gains and losses across all tumour samples, according to ASCAT analysis. The figure shows recurring gains and losses across all
tumour samples, relative to the ASCAT-estimate of ploidy for each tumour. Red = gains, green = losses, chromosome number along the x-axis, and
frequency of tumours with aberration on the y-axis. Peaks outside the dotted blue lines are aberrations found in 20 or more samples.
doi:10.1371/journal.pone.0126371.g003
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The analysis was also done for a third dataset including all tumours (all paired and single tu-
mours). Significant amplification peaks were identified on CFA13 for all the three tumour sets.
These significant regions includedMYC for the “all tumours” group and for one of the
Fig 4. Recurring gains and losses in three subgroups of CMTs, according to ASCAT analysis. The figure shows recurring gains and losses in three
subgroups of CMTs, relative to the ASCAT-estimate of ploidy for each tumour. Red = gains, green = losses, chromosome number along the x-axis, and
frequency of tumours with aberration on the y-axis.
doi:10.1371/journal.pone.0126371.g004
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selections with split tumour pairs. Significant regions of loss were observed for all three data
sets on CFA13, 24, 28 and 31. For selection one, loss on CFA8 and for selection two, loss on
CFA9 and CFA33, was also significant. However, the CFA33 loss was not significant consider-
ing all tumours together. These lost regions harbored genes like COL9A3 (CFA24), INPP5A
(CFA28), CYP2E1 (CFA28), and CRYAA (CFA31).
LOH and cnLOH
The regions with the highest frequency of loss of heterozygosity (LOH) were found on CFA8,
9, 13, 15, 18, 22, 24, 28, 31, 33, and X. These regions were orthologous to human chromosomes
14q32, 17q25, 8q24, 1p34/1p35, 7q21, 13q31, 20q13, 10q26, 21q22, 3q29 respectively [46]. A
corresponding location in the human genome was not found for the region on CFAX. Analysis
of the ASCAT output indicated that increased malignancy correlated with increased propor-
tion of probes with loss of heterozygosity. This was observed for both the three groups of hy-
perplasias, benign and malignant tumours and the six groups of morphologically similar
tumours. The two groups of most malignant tumours (including single, ductal, solid and ana-
plastic carcinomas) seemed to stand out from the rest (Figs 5 and 6). The same tendency was
seen for copy-number neutral events (cnLOH) (data not shown). cnLOH was defined as an al-
lelic bias for a SNP that was heterozygous in the germline, but without a change in total copy
number from the tumour ploidy [24]. Several homozygous deletions were identified in the re-
currently lost regions (Table 4). The genes COL9A3, INPP5A and CYP2E1 were found in the
Fig 5. Proportion of probes with LOH in subgroups of CMTs, according to ASCAT analysis. LOH: Loss
of heterozygosity. P: P-value from Kruskal-Wallis test.
doi:10.1371/journal.pone.0126371.g005
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regions with most frequently occurring homozygous deletions in each of the groups of hyper-
plasias, benign and malignant tumours. PTEN was the only gene from the Cancer Gene Census
List [44] that was found in regions with homozygous deletions in at least five tumours. Homo-
zygous deletion of PTEN was found in five tumours, four of them malignant. These four were
one anaplastic carcinoma, one simple tubular carcinoma and two complex carcinomas.
Histopathological parameters
To further dissect the CNAs with possible involvement in CMT pathogenesis, we looked at
chromosomal gains and losses associated with some histopathological parameters that are used
for evaluating tumour progression/malignancy. In general, the frequency of aberrations in-
creased if solid growth, invasive growth in tumour stroma and necrosis was present in the tu-
mour. Tumours with a myoepithelial cell component had a lower occurrence of aberrations
than tumours without such cells. The occurrence of CNAs also increased in tumours with a
moderate to severe nuclear pleomorphism compared to none and with a mitotic index above
nine per ten HPF compared to zero. Fig 7 delineates the chromosome-wise CNA pattern for
various morphological traits and shows that some aberrations might be associated with specific
histopathological parameters. Only chromosomes with regions with an aberration frequency
difference between parameter subgroups of20% (see Materials and Methods) are shown in
Fig 7. Many of the same chromosomes were affected by gains/losses for different histopatho-
logical parameters. However, gains in regions on CFA7, 17 and 37 and loss of regions on CFA2
and 8 seemed more specific to an increase in mitotic index. An increased frequency of losses in
regions on CFA36 was seen for moderate to severe nuclear pleomorphism compared to none,
while loss of regions on CFA30 was associated with invasive growth in tumour stroma.
Fig 6. Proportion of probes with LOH in groups of morphologically similar tumours, according to
ASCAT analysis. LOH: Loss of heterozygosity.
doi:10.1371/journal.pone.0126371.g006
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The chromosome region aberrations associated with changes in the histopathological pa-
rameters were studied for well-known cancer-associated genes.MYC was located in amplified
regions of CFA13 associated with moderate to severe nuclear pleomorphism, high mitotic
index and invasive growth into tumour stroma. The gained region on CFA20 that was associat-
ed with moderate to severe nuclear pleomorphism contained FHIT. RB1 was located in the fre-
quently lost region on CFA22 associated with solid growth, moderate to severe nuclear
pleomorphism, high mitotic index and invasive growth into tumour stroma. The tumour sup-
pressor gene SDHB was located in the region on CFA2 that was associated with high mitotic
index. The lost region on CFA18 was associated with solid growth and invasive growth into tu-
mour stroma included theMEN1 gene.
Discussion
In this study we have identified a large number of recurrent aberrations. This is in line with
previous studies of CNAs in human cancers [24,26,27]. There are few reports on CNAs in
CMTs, however, both a recent study of genomic aberrations in canine carcinomas as well as cy-
togenetic analysis of cell culture originating from CMTs showed widespread genomic alter-
ations [34,54]. Array-comparative genomic hybridization (aCGH) studies of canine
osteosarcomas and canine histiocytic sarcomas have also revealed highly complex tumours,
with aberrations ranging from numerous single locus CNAs to losses or gains of entire chro-
mosomes [55,56]. The wide range in number and types of chromosome level alterations in
CMTs is expected and probably reflects a combination of selection and particular failures in
Table 4. Genes in regions of homozygous deletions occurring in at least five tumours according to ASCAT.
Gene Human chromosome Canine chromosome Number of tumours with homozygous deletion
TNFRSF12A 16 6 5
PKD1 16 6 6
SEPX1 16 6 6
LOC448801 - 6 6
LOC100049001 - 6 6
HAGHL 16 6 6
AMN 14 8 8
PDE6G 17 9 7
ACTG1 17 9 7
SGSH 17 9 6
TIMP2 17 9 6
ELANE 19 20 5
MADCAM1 19 20 5
COL9A3 20 24 17
PTEN* 10 26 5
LIPF 10 26 5
INPP5A 10 28 15
CYP2E1 10 28 15
TFF3 21 31 5
TFF2 21 31 5
TFF1 21 31 5
CRYAA 21 31 11
* Gene found in the Cancer Gene Census list [40].
doi:10.1371/journal.pone.0126371.t004
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Fig 7. Chromosome-wise gains (red) and losses (green) for different histopathological parameters.
Gain/loss frequencies from the ASCAT analysis were used for these calculations. Only chromosomes with
regions with a CNA-frequency difference20% are shown (see Materials and Methods). The corresponding
contrasts between hyperplasias/malignant tumours and benign/malignant tumours are shown for
comparison. There were no regions with difference in frequency of loss20% for compared categories of the
parameters myoepithelial cells and necrosis. CFA: canine chromosome. SG: Solid growth (no/yes), MC:
Myoepithelial cells (yes/no), NP: Nuclear pleomorphism (no/moderate-severe), MI: Mitotic index (0/above 9
pr HBF), IG: Invasive growth, tumour stroma (no/yes), N: Necrosis (no/yes), H/M: Hyperplasia vs malignant,
B/M: Benign vs malignant.
doi:10.1371/journal.pone.0126371.g007
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genome surveillance mechanisms. The observation that the frequency of aberrations seemed to
be positively correlated with increased histopathological malignancy in all the three subgroup-
ings of the material is interesting. However, the tumour number in some of the carcinoma
groups is low, and for these the results must be interpreted with caution. Recurrent CNA losses
were more frequent than gains in the mammary tumours in this study, something which was
also previously seen in canine histiocytic sarcomas [55] and two of the single canine mammary
tumours studied by Bech et al [34]. Also, the observations of a high number of copy number
gains on CFA13 and few aberrations on CFA23 are similar to what has been found in other ca-
nine tumour types [56,57]. CFA16 was most often affected by recurrent copy number losses in
canine osteosarcoma and histiocytic sarcoma [55,56], while the proximal end of CFA27 was re-
ported to be deleted in four out of five canine mammary carcinomas [34]. However, other
chromosomes were affected by more deletions in the CMTs of the present study. This might re-
flect differences in genetic contributors between different tumours and cancer types, as has
been shown in recent studies of signatures of mutational processes in human cancers. These
identified both distinct variations and similarities regarding classes of mutations and mutation-
al patterns between (and within) different tumour types [58,59].
In addition to CNAs, aneuploidy clearly distinguishes cancer cells from normal cells. The
proportions of aneuploid hyperplasias and benign tumours in the present study were in line
with previous reports based on flow cytometric analysis of CMTs, while the proportion of an-
euploid malignant tumours in our study was lower. Rutteman et al. observed aneuploidy in
68.1% of mammary cancers and 17.4% of nonmalignant tumours [60], while the corresponding
numbers in a study Hellmén et al. were 54% of the histologically malignant, 13% of the histo-
logically benign tumours and 22% of the dysplastic mammary glands [61]. Aneuploidy was re-
ported in 45% of early-stage human breast carcinomas, which is somewhat higher than in the
malignant mammary tumours in our study [24]. The differences between the studies regarding
ploidy of malignant tumours might be due to biological variation, differences in analysis meth-
ods, change of classification guidelines of CMTs over time and different pathologists evaluating
the tumours. Although not large, we found a tendency of increased aneuploidy with increased
malignancy. Aneuploidy in benign tumours might reflect a malignant potential in these tu-
mours that is not yet shown by the histopathomorphology [60]. While aneuploidy has been
negatively associated with survival rates of dogs with diagnosed malignant mammary tumours
[62], others found no relationship between the incidence of aneuploidy and histological tu-
mour type, histological malignancy grade, nuclear grade or steroid receptor presence [60]. We
observed only two mammary tumours with hypodiploidy, in contrast to both Rutteman et al.
and Cornelisse et al. who reported hypodiploidy to be more frequent in dogs than in humans
as measured by flow cytometry [60,63]. It has been hypothesized that hypodiploidy might be
an early event in the canine mammary tumourigenesis, followed by multidiploidy or polyploi-
dy during tumour progression [60,62]. This is partly supported by studies of human breast can-
cer: e.g. the basal-like subtype often has a ploidy around 3n, and it has been suggested that the
genomes of these tumours initially are reduced from diploid to a partial haploid state (around
1.5n) before a whole-genome duplication to a ploidy around 3n [24]. A similar explanation
might apply to malignant tumours in our study with a ploidy ~3. Studies of human cancers
have also suggested that aneuploidy develops through an unstable tetraploid intermediate and
that genome doubling could act as a precursor to chromosomal instability [64]. The tendency
of an increased proportion of tetraploidy in benign CMTs compared to malignant and hyper-
plasias fits well with this theory.
The identified cancer-associated genes in the recurrently gained regions in the present sur-
vey were of dominant function/oncogenes only. Since copy number alterations in human
breast cancer have been shown to directly cause global deregulation of gene expression [65],
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and thereby may contribute to the development or progression of cancer, oncogenes can be ex-
pected to be located in amplified chromosomal regions of the tumour and genes with recessive
molecular function/tumour suppressor genes in deleted regions. Similarly to surveys of canine
mammary carcinomas and canine osteosarcomas [34,56], the frequently gained region on
CFA13 included theMYC gene in the mammary tumours of the present study. TheMYC re-
gion amplification was also among the identified significant aberrations. The proto-oncogene
MYC encodes a nuclear transcription factor (phosphoprotein) that plays an integral role in a
variety of cellular processes, such as cell growth, proliferation, metabolism, differentiation and
apoptosis [66].MYC, located on chromosome 8q24 in humans, harbors multiple, upstream
risk loci for human prostate, bladder, breast, and colorectal cancer [67]. In human breast can-
cer, amplification of theMYC gene is a quite frequent event [68,69]. Amplification ofMYC
seems to occur relatively late in tumourigenesis and is consistently observed in aggressive
forms of disease, correlating with poor prognosis and distant metastasis [68].MYC amplifica-
tion has also been suggested to be a driver of and selected for in the metastatic process [68].
The fact that we observed a higher proportion of the malignant than benign mammary tu-
mours with recurrent amplification in the region ofMYC correlates well with the known in-
volvement ofMYC in human breast cancer. PTEN was located in lost regions in mammary
tumours of the present study, which is in line with previous studies of canine cancers
[34,55,56]. Our observation of homozygous deletions of PTEN in several malignant mammary
tumours further indicates loss of PTEN as an important event in CMT development. PTEN is a
tumour suppressor gene that encodes the protein phosphatidylinositol-3,4,5-trisphosphate
3-phosphatase and plays an important role in inducing cell cycle arrest, programming apopto-
sis, regulation of cell adhesion, migration, and differentiation [70]. The PTEN gene is also one
of the most commonly mutated genes in human cancer [70], among them breast cancer
[27,71], and often suffers loss of heterozygosity (LOH) [72]. In addition to the amplification
and deletion of specific genes, CNAs might as well disrupt critical stoichiometric relationships
in cell metabolism and physiology (e.g. proteasome, mitotic spindle), possibly promoting fur-
ther instability and directly contributing to tumour development or progression [65]. The de-
tected copy number aberrations in regions without known annotated genes in the CMTs of
this study, e.g. the region on CFA9, could have such disruptive effects, contain hitherto un-
known genes/sequences associated with tumourigenesis or be random events due to genomic
instability.
The regions with the highest occurrence of LOH in our study did not show orthology to any
of the chromosome arms with frequent LOH found in in human breast cancer (HSA8p, 11q,
16q, 17p) [24]. However, similar to human breast cancer [24], many of the genomic regions
with a higher frequency of loss also harbored copy-number neutral events in the CMTs. The
genes COL9A3, INPP5A and CYP2E1, located in chromosomal regions for significant aberra-
tions and the highest frequency of homozygous deletions in our study, were not in the Gene
Cancer Census list [44]. Still, previous reports on cancer-association in humans and the func-
tion of the encoded protein, at least for INPP5A and CYP2E1, propose that they may play a
part in the CMT pathogenesis. COL9A3 encodes one of the three alpha chains of type IX colla-
gen, the major collagen component of hyaline cartilage. A homozygous missense mutation in
this gene has been detected in a human breast carcinoma [73,74]. INPP5A encodes membrane-
associated type I inositol 1,4,5-trisphosphate (InsP3) 5-phosphatase which is involved in medi-
ating cell responses to various stimuli [73]. Mutations in INPP5A have been found in several
cancers [74], and loss of the gene has been identified as an early event of human cutaneous
squamous cell carcinoma [75]. This is possibly also the case for CMTs, as we found the gene to
be homozygously deleted in hyperplasias, benign and malignant tumours. CYP2E1 encodes a
member of the cytochrome P450 superfamily of enzymes that is involved in metabolism of
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both endogenous and exogenous substrates. Polymorphisms in the CYP genes are associated
with risk of several cancer types [76]. CYP2E1 expression has been found to be both significant-
ly lower in malignant breast tissue compared to normal tissue in humans [77] and also lower in
tumours of clinical stage I compared to stage II-IV [78]. The loss of CYP2E1 in CMTs is in line
with these findings in human breast cancer.
As expected, some of the aberrations in regions of oncogenes and tumour suppressor genes
were common for changes in subgroups of histopathological parameters and tumour diagnosis
groups. In addition, loss of the well-known tumour suppressor RB1 was found to occur at a
higher frequency in tumours that had developed characteristics such as solid growth, moderate
to severe nuclear pleomorphism, high mitotic index and invasive growth into tumour stroma.
Aberrations in this gene is known from a variety of human tumours [79]. Highly recurrent loss
of RB1 was also found in canine histiocytic sarcomas [55]. The frequency of loss of this gene,
located on CFA22, was not as prominently different between the hyperplasias, benign and ma-
lignant tumours as for the histiopathological parameter subgroups. This fact illustrates how
studies of subgroups of histopathological parameters in more detail, in addition to histopatho-
logical diagnosis, have the potential to elucidate aberrations/genes associated with tumour
progression.
The main copy number aberration results of the present survey were confirmed by all three
algorithms used to study the CMTs, increasing the credibility of the findings. Precautions to re-
duce bias and technical artifacts through GC correction and normalization of the data prior to
analysis, combined with the limits for aberration calls in the algorithms, and finally focusing
on only the most highly recurrent aberrations in this large material of tumours, greatly reduce
the chance of reporting false aberration results or random findings. The observation of similar
aberrant regions and genes as previously described in both humans and canine cancers, espe-
cially the recent CMT survey by Beck et al. [34], also supports the validity of our results. How-
ever, functional evaluation of the copy number aberrations of the present study would greatly
add to our understanding of their importance in CMT development and should be addressed
in future studies.
Conclusion
The present study found that CNAs are common in CMTs and that the frequency of aberra-
tions and LOH increases with histopatholgical malignancy of the tumours. Amplification of
MYC and loss of PTEN, possibly also loss of COL9A3, INPP5A, CYP2E1, and RB1, may be im-
portant events in CMT development and progression. The recurrent amplification on CFA9
should be more extensively analyzed for its implication for CMT pathogenesis, and analysis of
chromosomal aberrations associated with histopathological parameters in more detail may aid
in identifying specific genes associated with CMT progression. Several similarities between
human and canine mammary neoplasias in case of recurrent CNAs further support the dog as
a valuable model for this disease in humans.
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